概述
-
货号
DVV00306
-
表达系统
Mammalian Cells -
种属反应性
SARS-CoV-2 (2019-nCoV) -
宿主
Human -
同种型
IgG1, kappa -
克隆类型
Monoclonal -
靶标
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2 -
浓度
1.34 mg/ml -
内毒素水平
Please contact with the lab for this information. -
纯度
>95% as determined by SDS-PAGE. -
纯化方式
Protein A/G purified from cell culture supernatant. -
Accession号
P0DTC2 -
克隆号
Etesevimab
-
应用
Research Grade Biosimilar -
状态
Liquid -
保存溶液
0.01M PBS, pH 7.4. -
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. -
别名
CB6, CB 6, CB-6, JS-016, JS016, JS 016, LY3832479, CAS: 2423948-94-9
图片
参考文献
- Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants. [DVV00306]
- Multiple SARS-CoV-2 variants exhibit variable target cell infectivity and ability to evade antibody neutralization. [DVV00306]
- Effects of the glycosylation of the receptor binding domain (RBD dimer)-based Covid-19 vaccine (ZF2001) on its humoral immunogenicity and immunoreactivity. [DVV00306]
- SARS-CoV-2 evolves to reduce but not abolish neutralizing action. [DVV00306]
评价
